Dr. Sam is a clinical heart failure cardiologist and a physician-scientist. She is translational researcher and is PI of her NIH funded lab. She is an expert in cardiac myocyte biology and in mechanisms of myocardial remodeling in cardiomyopathy, both in humans and animal models. She is a recognized expert in “heart failure with preserved ejection fraction” (HFpEF) /diastolic heart failure and “heart failure with reduced ejection fraction” (HFrEF)/systolic heart failure and cardiomyopathies
The Sam lab is focused on three major areas of investigation:
1) Pro-inflammatory and pro-fibrotic mechanisms that mediate cardiac remodeling in heart failure, cardiac hypertrophy and hypertension.
2) Investigating the relationship between matrix markers and heart failure in humans with cardiac amyloid and scleroderma.
3) Investigating cross talk between adipocyte-derived factors, myokines and cardiokines in heart failure.
all of which are directed to novel pathways to provide therapeutic insights into drug development
- Active Staff Hospital Privileges, Medicine, Boston Medical Center
- University of the Witwatersrand, MD
- Published on 6/27/2016
Tanaka K, Valero-Muñoz M, Wilson RM, Essick EE, Fowler CT, Nakamura K, van den Hoff M, Ouchi N, Sam F. Follistatin like 1 Regulates Hypertrophy in Heart Failure with Preserved Ejection Fraction. JACC Basic Transl Sci. 2016 Jun; 1(4):207-221. PMID: 27430031.
- Published on 1/1/2016
Valero-Muñoz M, Li S, Wilson RM, Hulsmans M, Aprahamian T, Fuster JJ, Nahrendorf M, Scherer PE, Sam F. Heart Failure With Preserved Ejection Fraction Induces Beiging in Adipose Tissue. Circ Heart Fail. 2016 Jan; 9(1):e002724. PMID: 26721917.
- Published on 12/11/2015
Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC. Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study. Circulation. 2016 Jan 19; 133(3):282-90. PMID: 26660282.
- Published on 11/21/2015
Hulsmans M, Sam F, Nahrendorf M. Monocyte and macrophage contributions to cardiac remodeling. J Mol Cell Cardiol. 2016 Apr; 93:149-55. PMID: 26593722.
- Published on 7/20/2015
Lindsey ML, Mayr M, Gomes AV, Delles C, Arrell DK, Murphy AM, Lange RA, Costello CE, Jin YF, Laskowitz DT, Sam F, Terzic A, Van Eyk J, Srinivas PR. Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation. 2015 Sep 1; 132(9):852-72. PMID: 26195497.
- Published on 4/22/2015
Tahir U, Sam F. Withdrawal of heart failure medications in peripartum cardiomyopathy after myocardial recovery. Int J Cardiol. 2015 Jul 1; 190:212-3. PMID: 25920029.
- Published on 2/24/2015
Tahir U, Doros G, Sam F. Delayed myocardial recovery in peripartum cardiomyopathy. Int J Cardiol. 2015 Apr 1; 184:310-2. PMID: 25731846.
- Published on 12/15/2014
Brogan A, Ding Y, Pimentel DR, Sam F. Non-invasive imaging for cardiac amyloidosis - delaying the obvious? Int J Cardiol. 2014 Dec 15; 177(2):e87-9. PMID: 25456697.
- Published on 8/22/2014
Tanaka K, Wilson RM, Essick EE, Duffen JL, Scherer PE, Ouchi N, Sam F. Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. Circ Heart Fail. 2014 Nov; 7(6):976-85. PMID: 25149095.
- Published on 11/23/2013
Quiroz R, Doros G, Shaw P, Liang CS, Gauthier DF, Sam F. Comparison of characteristics and outcomes of patients with heart failure preserved ejection fraction versus reduced left ventricular ejection fraction in an urban cohort. Am J Cardiol. 2014 Feb 15; 113(4):691-6. PMID: 24484862.
View 50 more publications: View full profile at BUMC